Laurus Labs Limited
Momentum (100/100) does the heavy lifting; valuation (1/100) is the drag.
ExpensiveOvervaluedLaurus Labs Limited earns a Hold from StocksWizard, with a blended score of 45/100. At ₹1,781.3 it trades above our blended DCF and relative-multiples fair value of ₹890.65, about 50% downside to that estimate — we read it as overvalued by 50%. On 88.5x trailing earnings it sits pricier than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹1,781.3. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. The average analyst target of ₹1,055.15 implies about 41% downside across 13 analysts. It clears 8 of 13 investability checks, with durability 64, valuation 1 and momentum 100 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹712.52.
Analyst views
1-year price
EOD · 2026-07-2952-week range
+0.00% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 7/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 17.7%
- Pass: Low debt (D/E < 0.5): 0.46x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 5%
- Pass: Earnings growing: 19%
- Pass: Net margin ≥ 10%: 13.0%
- Fail: Current ratio > 1.5: 1.33
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 10.65
- Pass: Piotroski ≥ 7: 7/9
Quarterly results
Annual financials
Shareholding
- Promoter32.0%
- Institutions30.4%
- Public & other37.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Trading near its 52-week high.
- Financially solid — Altman Z 10.65.
- High Piotroski quality score (7/9).
Opportunities
- Earnings growing (19% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Laurus Labs Limited
Laurus Labs Limited manufactures and sells generic medicines and active pharmaceutical ingredients across India and international markets. The company produces oral solid formulations and APIs for antiretroviral, antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapies, along with biotechnology services for nutraceutical and dietary supplement applications.
Laurus Labs Limited — frequently asked questions
Is Laurus Labs Limited a buy, hold or sell?
StocksWizard currently rates Laurus Labs Limited (LAURUSLABS) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Laurus Labs Limited's fair value?
Our blended DCF and relative-valuation model estimates Laurus Labs Limited's fair value at about ₹890.65, versus a current price of ₹1,781.3 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Laurus Labs Limited financially healthy?
Laurus Labs Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.
How has Laurus Labs Limited's share price performed?
Laurus Labs Limited is up 62% over three months, and last traded at ₹1,781.3. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.